Throughout the COVID-19 pandemic, which started when the first novel acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified during the outbreak in the China's Wuhan in December 2019, people who fell victim to it, whether vaccinated or not, have often laid hopes that their antibodies might protect against a reinfection by new variants.
